Lv2
180 积分 2024-05-05 加入
Precision medicine for multiple myeloma: The case for translocation (11;14)
5个月前
已完结
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
5个月前
已完结
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
5个月前
已完结
Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
5个月前
已关闭
Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
5个月前
已关闭
Selinexor for the treatment of patients with relapsed or refractory multiple myeloma
5个月前
已完结
Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
5个月前
已完结
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
5个月前
已完结
Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
5个月前
已完结
Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction
5个月前
已完结
皖公网安备34019202002308
